Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes (NCT06390748) | Clinical Trial Compass
CompletedPhase 2
Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
China150 participantsStarted 2021-01-01
Plain-language summary
Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.
Who can participate
Age range
18 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients aged between 18 and 90 years.
. Diagnosed with sepsis or septic shock according to the diagnostic criteria in Suivival Sepsis of 2021.
. Received adequate fluid resuscitation and necessary exogenous Norepinephrine (NE).
. No contraindications to Esmolol and appropriate heart rate levels determined by clinical assessment.
. Provided written informed consent.
Exclusion criteria
. Deceased within three days following ICU admission.
. Pregnant or lactating individuals.
. Underwent surgical procedures within the last two weeks.
. Severe cardiac failure exceeding NYHA Class III.
. Usage of long-term oral β-blockers or any form of extracorporeal circulation within the last two weeks.
. Presenting with sinus bradycardia or atrioventricular block.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Impact of Esmolol on Survival Rates
Timeframe: Survival rates will be monitored from the time of randomization until the end of the study period or until patient death, whichever comes first, up to 28 days post-randomization.
2
Improvement in Organ Function and Inflammatory Markers
Timeframe: Organ function and inflammatory markers will be measured at baseline, then regularly throughout the patient's stay in the ICU, up to a maximum of 28 days.
. Received high doses of corticosteroids in the past three months.
. Underwent significant hormone therapy, persistent blood loss of more than 500 ml within any 24-hour period, or were treated with Esmolol for less than three days.